The Role of Dysmyelination in Cognitive Impairment of Psychotic Spectrum Disorders

Sponsor

NYU Langone Health (Other)

Overall Status

Recruiting

CT.gov ID

NCT03166098

Collaborator

(none)

210

Enrollment

Location

67.8

Anticipated Duration (Months)

3.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a single center study that uses both between-group comparisons and correlational analyses to establish biomarkers of dysmyelination and cognitive impairment in Psychotic Spectrum Disorders using imaging and neuropsychological assays.The study will provide non-invasive biomarkers of cognitive dysfunction in Psychotic Spectrum Disorder.

Condition or Disease	Intervention/Treatment	Phase
Schizophrenia Bipolar Disorder	Diagnostic Test: Cognitive Function Assessments

Study Design

Study Type:

Observational

Anticipated Enrollment :

210 participants

Observational Model:

Case-Control

Time Perspective:

Prospective

Official Title:

The Role of Dysmyelination in Cognitive Impairment of Psychotic Spectrum Disorders

Actual Study Start Date :

Jul 5, 2016

Anticipated Primary Completion Date :

Mar 1, 2022

Anticipated Study Completion Date :

Mar 1, 2022

Arms and Interventions

Arm	Intervention/Treatment
Diagnosis of Schizophrenia	Diagnostic Test: Cognitive Function Assessments The NIMH-Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) is a consensus battery that is considered state-of-the art in the evaluation of cognitive skills for schizophrenia research.(Burton et al., 2013, Harvey, 2014) The complete cognitive battery takes about one hour to administer, and is comprised of 10 subtests measuring seven essential domains of function, with very good reliability and validity.(Nuechterlein 2008, August et al., 2012) The MATRICS subtests have been incorporated into the cognitive battery described below, with supplementary subtests included where indicated within each domain.
Diagnosis of Bipolar Disorder	Diagnostic Test: Cognitive Function Assessments The NIMH-Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) is a consensus battery that is considered state-of-the art in the evaluation of cognitive skills for schizophrenia research.(Burton et al., 2013, Harvey, 2014) The complete cognitive battery takes about one hour to administer, and is comprised of 10 subtests measuring seven essential domains of function, with very good reliability and validity.(Nuechterlein 2008, August et al., 2012) The MATRICS subtests have been incorporated into the cognitive battery described below, with supplementary subtests included where indicated within each domain.
Unaffected siblings of the SZ groups	Diagnostic Test: Cognitive Function Assessments The NIMH-Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) is a consensus battery that is considered state-of-the art in the evaluation of cognitive skills for schizophrenia research.(Burton et al., 2013, Harvey, 2014) The complete cognitive battery takes about one hour to administer, and is comprised of 10 subtests measuring seven essential domains of function, with very good reliability and validity.(Nuechterlein 2008, August et al., 2012) The MATRICS subtests have been incorporated into the cognitive battery described below, with supplementary subtests included where indicated within each domain.
Unaffected siblings of the BP group	Diagnostic Test: Cognitive Function Assessments The NIMH-Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) is a consensus battery that is considered state-of-the art in the evaluation of cognitive skills for schizophrenia research.(Burton et al., 2013, Harvey, 2014) The complete cognitive battery takes about one hour to administer, and is comprised of 10 subtests measuring seven essential domains of function, with very good reliability and validity.(Nuechterlein 2008, August et al., 2012) The MATRICS subtests have been incorporated into the cognitive battery described below, with supplementary subtests included where indicated within each domain.
Healthy control (HC) comparison group	Diagnostic Test: Cognitive Function Assessments The NIMH-Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) is a consensus battery that is considered state-of-the art in the evaluation of cognitive skills for schizophrenia research.(Burton et al., 2013, Harvey, 2014) The complete cognitive battery takes about one hour to administer, and is comprised of 10 subtests measuring seven essential domains of function, with very good reliability and validity.(Nuechterlein 2008, August et al., 2012) The MATRICS subtests have been incorporated into the cognitive battery described below, with supplementary subtests included where indicated within each domain.

Outcome Measures

Primary Outcome Measures

DKI(metrics RDextra, faxon, and ADextra) Metrics [6 Years]
To compare DKI metrics (faxon, RDextra, and ADextra) in patients with SZ or BP, their unaffected siblings (SIB), and healthy comparison control (HC) subjects
Magnetic Resonance Spectroscopy will be employed to obtain quantitative metrics of choline (Cho) [1 Hour]
Choline Concentration (1H-MRS)

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 30 Years

Sexes Eligible for Study:

All

Inclusion Criteria:

Patients:

current DSM-5-defined diagnosis of a schizophrenia or bipolar disorder. A best estimate diagnostic approach will be utilized in which information from the Diagnostic Interview for Genetic Studies (DIGS) is supplemented by information from family informants, psychiatrists, and medical records to generate a diagnosis as needed
no alcohol or substance abuse during the last 6 month
no current substance-induced psychotic disorder or a psychotic disorder due to a general medical condition determined by DSM-5 criteria
ages 18 to 30 years old;
any race
competent and willing to sign informed consent
within 5 years from the disease onset.

Siblings:

have the same biological parents as their PSD sibling
any race
no current or past history of psychotropic medication usage
no alcohol or substance abuse during the last 6 months
competent and willing to sign informed consent;
ages 18 to 30 years old.

Healthy controls:

matched for age to PSD patients
no current or past history of psychotropic medication usage
no prodromal symptoms and no family history of PSD
no alcohol or substance abuse during the last 6 months
competent and willing to sign informed consent.
all attempts will be made to recruit controls with similar parental SES as patients. However, given that PSD are both a neurodevelopmental and familial disorder, exact matching for educational level or IQ may neither be possible nor desirable.

have the same biological parents as their PSD sibling

any race
no current or past history of psychotropic medication usage
no alcohol or substance abuse during the last 6 months
competent and willing to sign informed consent;
ages 18 to 30 years old.

Exclusion Criteria:

a serious neurological or endocrine disorder or any medical condition or treatment known to affect the brain, 2) organic brain disorder, mental retardation, or significant medical illness;
significant risk of suicidal or homicidal behavior;
must not have met DSM-5 criteria for current alcohol or drug dependence in the last 6 months;
contraindications to MRI scanning (i.e., metal implants, pacemakers, pregnancy, etc.);
documented loss of consciousness (LOC) for longer than 30 minutes or LOC with any neurological sequelae.